Aurobindo Pharma’s wholly owned subsidiary, CuraTeQ Biologics, has signed a marketing and distribution agreement with European healthcare giant STADA Arzneimittel AG. The deal covers two EMA-approved biosimilars developed by CuraTeQ, focusing on select European Union territories, notably France and Germany. This strategic partnership aims to leverage STADA’s established network to expand CuraTeQ’s market reach and drive significant revenue growth across the EU.
Strategic European Partnership Secured
Aurobindo Pharma Limited announced today, March 25, 2026, a major commercial development for its biosimilars pipeline. CuraTeQ Biologics Pvt Ltd, the company’s subsidiary focused on biosimilars, has successfully entered into a definitive marketing and distribution agreement with STADA Arzneimittel AG, a leading European healthcare and pharmaceuticals company.
Scope of the Distribution Agreement
Under the terms of this new agreement, STADA will be responsible for the marketing and distribution of two biosimilars developed by CuraTeQ. These products have already received approval from the European Medicines Agency (EMA). The initial focus for distribution will be key markets within the European Union, specifically naming France and Germany.
To facilitate market entry, new brand names will be created and registered specifically for each biosimilar product in these territories. This move is anticipated to significantly enhance CuraTeQ’s overall market penetration and accelerate revenue realization from its development pipeline.
Expected Impact on CuraTeQ
Management stated that this agreement is strategic, designed to effectively expand CuraTeQ’s market reach across the continent, drive robust revenue growth, and capitalize on STADA’s deep and established distribution infrastructure within the highly regulated EU markets. The collaboration is viewed as a critical step in realizing the commercial potential of CuraTeQ’s innovative biologics portfolio.
Source: BSE
